Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Covax-19 therapeutic vaccine in SARS-CoV-2 infected patients
NCT04428073Phase 1Unknown
- Sponsor
- GeneCure Biotechnologies
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label trial of SimVec-based COVID-19 vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by GeneCure Biotechnologies. Primary endpoint: Safety (Adverse Events and Laboratory Abnormalities) at 26 weeks. Status: unknown.
02
Drugs
SimVec-based COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04428073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428073.